{"id":"aripiprazole-abilify","safety":{"commonSideEffects":[{"rate":"10-25%","effect":"Akathisia (restlessness)"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Anxiety"},{"rate":"5-15%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike typical antipsychotics that block dopamine receptors, aripiprazole acts as a partial agonist, meaning it can both stimulate and inhibit dopamine signaling depending on baseline dopamine levels. This unique mechanism allows it to reduce excessive dopamine activity in psychotic states while maintaining adequate dopamine function in other brain regions, potentially reducing extrapyramidal side effects. Its additional activity at serotonin 5-HT1A receptors contributes to its efficacy in mood and anxiety symptoms.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopamine and serotonin neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:01.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic and mixed episodes, maintenance)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"},{"name":"Tourette's disorder"}]},"trialDetails":[{"nctId":"NCT03485417","phase":"PHASE2, PHASE3","title":"Substance Misuse To Psychosis for Stimulants","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence","enrollment":165},{"nctId":"NCT07483294","phase":"","title":"Cerebellum-based Imaging Neural Markers for Antipsychotic Response","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-11-01","conditions":"Psychosis; Acute","enrollment":120},{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT04903353","phase":"PHASE4","title":"Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-02-01","conditions":"Weight Gain, Autism Spectrum Disorder, Medication Side Effect","enrollment":31},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT05662306","phase":"PHASE4","title":"C-Cog in Early Course Schizophrenia Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2024-01-23","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT03238326","phase":"PHASE3","title":"Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-08-23","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT03442101","phase":"","title":"Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2018-04-01","conditions":"Psychosis","enrollment":156},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06236451","phase":"PHASE4","title":"Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-04-05","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT07215884","phase":"PHASE1","title":"Dopamine and Sensorimotor Function in Stuttering","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-30","conditions":"Stuttering, Adult","enrollment":40},{"nctId":"NCT00288353","phase":"PHASE3","title":"Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":48},{"nctId":"NCT05545891","phase":"PHASE2","title":"Aripiprazole in Body Focused Repetitive Behaviors","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06","conditions":"Trichotillomania (Hair-Pulling Disorder), Dermatillomania","enrollment":100},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT07153406","phase":"PHASE3","title":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2025-09-15","conditions":"Depressive Disorder","enrollment":220},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT01490086","phase":"PHASE2","title":"RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Reviva Pharmaceuticals","startDate":"2011-12","conditions":"Acute Schizophrenia, Schizoaffective Disorder","enrollment":234},{"nctId":"NCT05169268","phase":"","title":"Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-02-01","conditions":"Schizophrenia and Related Disorders, Anxiety Depression","enrollment":10},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":"Major Depressive Disorder (MDD)","enrollment":400},{"nctId":"NCT05686772","phase":"","title":"Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis","status":"COMPLETED","sponsor":"Laval University","startDate":"2019-11-01","conditions":"Gambling Disorder, Psychotic Disorders","enrollment":520},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT06969755","phase":"PHASE4","title":"Biomarkers to Enhance Early Schizophrenia Treatment","status":"NOT_YET_RECRUITING","sponsor":"Northwell Health","startDate":"2025-07-30","conditions":"Schizophenia Disorder","enrollment":180},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03874494","phase":"PHASE3","title":"Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2019-11-27","conditions":"Schizophrenia","enrollment":371},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT04812379","phase":"","title":"Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2021-04-07","conditions":"Bipolar Disorder I","enrollment":535},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT06799559","phase":"PHASE3","title":"Study on the Efficacy and Safety of QLM1016 in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-05","conditions":"Schizophrenia","enrollment":402},{"nctId":"NCT05361993","phase":"PHASE4","title":"Efficacy of Biofeedback in the Treatment of Tic Disorder","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2024-06-01","conditions":"Tic Disorders","enrollment":""},{"nctId":"NCT05322031","phase":"PHASE4","title":"The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-08-01","conditions":"Schizophrenia, Myelin Degeneration, Cognition Disorder","enrollment":15},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT05942716","phase":"PHASE2","title":"Serotonin Control of Impulsivity in Tourette Disorder","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-24","conditions":"Tourette Disorder","enrollment":25},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06613334","phase":"NA","title":"Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses","status":"RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2024-10-04","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT06589817","phase":"PHASE3","title":"A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2024-10","conditions":"Acute Schizophrenia","enrollment":376},{"nctId":"NCT06590298","phase":"PHASE4","title":"Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females","status":"NOT_YET_RECRUITING","sponsor":"Universiti Putra Malaysia","startDate":"2024-09-15","conditions":"Psychosis, Metabolic Syndrome, Weight Gain","enrollment":600},{"nctId":"NCT02918370","phase":"PHASE3","title":"Aripiprazole for Bipolar Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-11","conditions":"Bipolar Disorder, Alcoholism, Alcohol Abuse","enrollment":75},{"nctId":"NCT03423680","phase":"PHASE3","title":"A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","status":"RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-02-22","conditions":"Depression, Bipolar","enrollment":390},{"nctId":"NCT01617460","phase":"PHASE3","title":"A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-09","conditions":"Autistic Disorder","enrollment":86},{"nctId":"NCT06372210","phase":"NA","title":"A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-06-26","conditions":"Mental Disorder, Schizophrenia, Major Depressive Disorder","enrollment":54},{"nctId":"NCT06501339","phase":"PHASE4","title":"Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-08-10","conditions":"Clozapine Resistant Schizophrenia","enrollment":40},{"nctId":"NCT03522168","phase":"","title":"Long-term Antipsychotic Pediatric Safety Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-10","conditions":"Weight, Body","enrollment":509},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT06373770","phase":"NA","title":"Effects of Ayres Sensory Integration Therapy Versus Conservative Treatment in Autism Spectrum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Superior University","startDate":"2023-10-01","conditions":"Autism Spectrum Disorder","enrollment":30},{"nctId":"NCT06054321","phase":"NA","title":"Psychopharmacotherapy for Depressive Patients","status":"RECRUITING","sponsor":"Chonnam National University Hospital","startDate":"2022-08-03","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT02822092","phase":"","title":"Striatal Connectivity and Clinical Outcome in Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2016-07","conditions":"Psychotic Disorders","enrollment":196},{"nctId":"NCT05389046","phase":"NA","title":"Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-08-15","conditions":"Outpatients / Inpatients With Depression","enrollment":252},{"nctId":"NCT05554627","phase":"PHASE4","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2023-10-27","conditions":"Depressive Disorder, Major","enrollment":""},{"nctId":"NCT03198078","phase":"PHASE3","title":"Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-30","conditions":"Schizophrenia","enrollment":316},{"nctId":"NCT04203056","phase":"PHASE4","title":"Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-12-16","conditions":"Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder","enrollment":15},{"nctId":"NCT04030143","phase":"PHASE1, PHASE2","title":"A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-01","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":266},{"nctId":"NCT02357849","phase":"PHASE4","title":"Fluoxetine vs Aripiprazole Comparative Trial (FACT)","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2014-07","conditions":"Attenuated Psychosis Syndrome","enrollment":9},{"nctId":"NCT06128408","phase":"","title":"The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-12-01","conditions":"Treatment-resistant Schizophrenia","enrollment":300},{"nctId":"NCT00202007","phase":"PHASE2","title":"Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2005-02","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT05473741","phase":"","title":"Risk of Breakthrough Symptoms With Long-Acting Injectable Medications","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-09","conditions":"Schizophrenia, Schizophrenia Relapse","enrollment":180},{"nctId":"NCT05974241","phase":"PHASE4","title":"Irritability in Children With ADHD and Emotion Dysregulation","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-04-21","conditions":"Irritable Mood, ADHD","enrollment":36},{"nctId":"NCT05766540","phase":"PHASE4","title":"Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-20","conditions":"Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia","enrollment":60},{"nctId":"NCT05868720","phase":"NA","title":"EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-07-01","conditions":"The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level","enrollment":42},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT00261443","phase":"PHASE4","title":"A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":1270},{"nctId":"NCT05804721","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-10-10","conditions":"Healthy","enrollment":29},{"nctId":"NCT05103410","phase":"PHASE4","title":"Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-10","conditions":"Anesthesia, Analgesia, Hysterotomy","enrollment":80},{"nctId":"NCT03919994","phase":"","title":"Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2019-03-28","conditions":"Schizophrenia","enrollment":338},{"nctId":"NCT05646264","phase":"PHASE4","title":"A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2023-01-01","conditions":"Schizophrenia, Negative Symptoms in Schizophrenia","enrollment":220},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01354353","phase":"PHASE1","title":"A Study of Safety and Tolerability in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT02955654","phase":"NA","title":"Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder","status":"WITHDRAWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT05532254","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2021-02-14","conditions":"Healthy Subjects","enrollment":31},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT01328093","phase":"PHASE3","title":"A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients","status":"TERMINATED","sponsor":"Denovo Biopharma LLC","startDate":"2011-04","conditions":"Schizophrenia","enrollment":678},{"nctId":"NCT00276978","phase":"PHASE3","title":"Aripiprazole Augmentation Therapy in Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"University Hospital Freiburg","startDate":"2005-06","conditions":"Therapy-resistant Depression","enrollment":""},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT04907279","phase":"","title":"Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)","status":"UNKNOWN","sponsor":"Otsuka Canada Pharmaceutical Inc.","startDate":"2021-11-01","conditions":"Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder","enrollment":200},{"nctId":"NCT00484471","phase":"PHASE4","title":"ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka International Asia Arab","startDate":"2007-10","conditions":"Bipolar Disorder","enrollment":127},{"nctId":"NCT03408873","phase":"PHASE4","title":"CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)","status":"COMPLETED","sponsor":"Martha Sajatovic","startDate":"2018-04-01","conditions":"Bipolar Disorder, Medication Adherence, Medication Non Adherence","enrollment":30},{"nctId":"NCT03386851","phase":"","title":"Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2016-12-13","conditions":"Schizophrenia, Bipolar 1 Disorder","enrollment":1030},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT00468130","phase":"NA","title":"Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Autism","enrollment":13},{"nctId":"NCT01123707","phase":"PHASE3","title":"To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":173}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"NAUSEA"},{"count":2,"reaction":"SOMNOLENCE"},{"count":2,"reaction":"SPEECH DISORDER"},{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"ABDOMINAL PAIN LOWER"},{"count":1,"reaction":"ADVERSE REACTION"},{"count":1,"reaction":"ARTHRITIS"},{"count":1,"reaction":"ASCITES"},{"count":1,"reaction":"BLOOD LACTIC ACID ABNORMAL"},{"count":1,"reaction":"BLOOD POTASSIUM DECREASED"}],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"aripiprazole (Abilify)","genericName":"aripiprazole (Abilify)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopamine and serotonin neurotransmission in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic and mixed episodes, maintenance), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}